NiceR

NiceR appears to refer to a **preclinical enzyme-based therapeutic candidate** associated with Hansa Biopharma. Publicly accessible information is sparse and does not clearly disclose a validated international nonproprietary name, precise molecular composition, dosage form, route, or detailed mechanism beyond being described as a cysteine endopeptidase and an enzyme stimulator in drug intelligence databases. Based on the limited information available, it is best treated as an investigational pharmaceutical asset rather than an approved marketed medicine, with reported research interest in immune and oncology settings such as autoimmune disease, graft rejection, and neoplasms.